{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:55:31Z","timestamp":1740135331114,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) receptor, is registered for migraine prevention. Compared to other conventional migraine prevention medicines (i.e. topiramate, betablockers and amitriptyline) erenumab has better tolerability. Impaired hemostasis has not been reported previously. Here, we report the first case of an increased tendency to bruise in a migraine patient treated with erenumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 41-year old female migraine patient was treated with erenumab for 12\u00a0months, which led to a significant reduction of headache and migraine days. Three months after treatment start, she experienced increased tendency to bruise leading to extreme ecchymosis after 4\u00a0months treatment. Platelet counts and aggregation, thromboelastography, activated partial thromboplastin time (APTT) and international normalized ratio (INR) were all normal. Thorough interview revealed intake of fish oil supplements for many years prior to treatment. The increased tendency to bruise subsided after discontinuation of fish oil supplements.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The combination of fish oil supplements and erenumab may cause increased tendency to bruise. Erenumab has no effect on the platelets per se but may cause impaired wound healing by suppression of CGRP. Thus, small and unnoticeable bruises may be aggravated instead in patients with tendency to bruise caused by for instance fish oil supplements.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02294-6","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T05:02:48Z","timestamp":1625202168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"C. K.","family":"Cullum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. K.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. B.","family":"Kocadag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3803-3599","authenticated-orcid":false,"given":"F. M.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"2294_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"LH Lassen","year":"2002","unstructured":"Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia. 2002;22:54\u201361.","journal-title":"Cephalalgia"},{"key":"2294_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M. Migraine. N Engl J Med. 2020;383:1866\u201376.","journal-title":"N Engl J Med"},{"key":"2294_CR3","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1177\/0333102419854082","volume":"39","author":"M Ashina","year":"2019","unstructured":"Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019;39:1455\u201364.","journal-title":"Cephalalgia"},{"key":"2294_CR4","first-page":"CD003177","volume":"3","author":"AS Abdelhamid","year":"2020","unstructured":"Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3:CD003177.","journal-title":"Cochrane Database Syst Rev"},{"key":"2294_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jnutbio.2014.05.001","volume":"25","author":"M Phang","year":"2014","unstructured":"Phang M, Scorgie FE, Seldon M, et al. Reduction of prothrombin and factor V levels following supplementation with omega-3 fatty acids is sex dependent: a randomised controlled study. J Nutr Biochem. 2014;25:997\u20131002.","journal-title":"J Nutr Biochem"},{"key":"2294_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1055\/s-0037-1614865","volume":"82","author":"G Andrioli","year":"1999","unstructured":"Andrioli G, Carletto A, Guarini P, et al. Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion. Thromb Haemost. 1999;82:1522\u20137.","journal-title":"Thromb Haemost"},{"key":"2294_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.yrtph.2019.05.013","volume":"106","author":"JL Bussiere","year":"2019","unstructured":"Bussiere JL, Davies R, Dean C, et al. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol. 2019;106:224\u201338.","journal-title":"Regul Toxicol Pharmacol"},{"key":"2294_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jdermsci.2014.02.001","volume":"74","author":"J Ch\u00e9ret","year":"2014","unstructured":"Ch\u00e9ret J, Lebonvallet N, Buh\u00e9 V, Carre JL, Misery L, Le Gall-Ianotto C. Influence of sensory neuropeptides on human cutaneous wound healing process. J Dermatol Sci. 2014;74:193\u2013203.","journal-title":"J Dermatol Sci"},{"key":"2294_CR9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1177\/0333102420933571","volume":"40","author":"S Wurthmann","year":"2020","unstructured":"Wurthmann S, N\u00e4gel S, Hadaschik E, et al. Impaired wound healing in a migraine patient as a possible side effect of calcitonin gene-related peptide receptor antibody treatment: a case report. Cephalalgia. 2020;40:1255\u201360.","journal-title":"Cephalalgia"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02294-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T05:04:37Z","timestamp":1625202277000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02294-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02294-6","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"21 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient gave her written informed consent to publish this case report, including images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CKC, MKO, HBK report no conflicting interests. MA is a consultant, speaker or scientific advisor for AbbVie, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva, primary investigator for AbbVie, Amgen, Eli Lilly, Lundbeck, and Novartis trials. MA serves as associate editor of Cephalalgia, Headache, and Journal of Headache and Pain. MA is the President of the International Headache Society. FMA is a consultant, speaker of scientific advisor for Eli Lilly, Novartis, Teva, Lundbeck, and primary investigator for Novartis and Teva trials. FMA serves as associate editor for Headache Medicine. FMA is the President of the Danish Headache Society.None of the authors (CKC, MKO, HBK, MA, FMA) report any ownership interest and do not own stocks of any pharmaceutical company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"257"}}